Compare New York Times Co (NYT) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Stryker Corporation — how do they compare? New York Times Co trades at $66.32 (market cap $10.74B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 9.9× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Stryker Corporation for 21 Days on average.
| NYT | SYK | |
|---|---|---|
Market Cap | $10.74B | $106.24B |
Volume | 2,096,352 | 2,982,001 |
Sector | Media | Health |
52-Week High | $85.86 | $388.35 |
52-Week Low | $54.66 | $269.75 |
Typical Hold Time | 81 Days | 21 Days |
Enterprise Value | $10.14B | $117.70B |
Dividend Yield | 1.38% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.60, up 2.62% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. Technical indicators show a bullish overall signal despite mixed moving averages, with key resistance at $67-68. The company maintains robust profitability with 13.19% net income margin and recently declared a $0.23 quarterly dividend payable October 22, 2026.
NYT presents a favorable investment case with 35% analyst buy ratings and $84 consensus price target suggesting 26% upside potential. Key opportunities include sustained digital subscription growth and AI-related legal developments, while risks involve the ongoing shareholder lawsuit alleging reporting bias and competitive pressures in digital media. The stock's current valuation at 27.75 P/E appears justified by its earnings trajectory.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
